|Articles|December 30, 2013

Segment 2 - Histology, Targeted Therapy and Surgery

Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”

The panel also discusses targeted therapy and surgery in treatment of NSCLC.

Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”


Related to this article

CAR T-cell therapy | Image: AdobeStock
In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."